50.55 USD
↗ 0.64 (1.28%)AT CLOSE (03:59 PM EDT)
Rigel Pharmaceuticals Inc. (New)
RIGLNASDAQ • USD
50.30
↘ 0.25 (0.49%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
50.30
↘ 0.25 (0.49%)
Market: CLOSED
Rigel Pharmaceuticals Inc. (New) (RIGL) is currently trading at $50.52. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (75.7%), a bullish Golden Cross on the moving averages and bullish moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Oct 27, 2026.
Open?$50.09
High?$50.70
Low?$49.54
Prev. Close?$49.91
Volume?133.1K
Avg. Volume?228.2K
VWAP?$50.11
Rel. Volume?0.58x
Bid / Ask
Bid?$49.50 × 100
Ask?$50.85 × 1.0K
Spread?$1.35
Midpoint?$50.18
Valuation & Ratios
Market Cap?944.3M
Shares Out?18.5M
Float?16.7M
Float %?89.5%
P/E Ratio?2.93
P/B Ratio?2.22
EPS?$17.23
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Themes
Address
611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-1100
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-1100
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?96
Momentum?23
Short Sent.?39
Piotroski F-Score?2/9Weak
Altman Z-Score?4.46Safe
Confidence?51%Low
Short InterestVery High
Short % of Float?16.34%High
Short Interest?2.7M
Days to Cover?12.8
Free Float16.7M
Avg Daily Volume213.5K
Settlement Date2026-10-15
Financial Health
Current Ratio?1.94Adequate
Quick Ratio?1.79Adequate
Cash Ratio?0.64Adequate
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score89/100
P/E?2.9CHEAP▾
Peers100
S&P97
P/B?2.22CHEAP▾
Peers100
S&P69
P/S?3.41FAIR▾
Peers100
S&P45
P/FCF?11.9CHEAP▾
Peers100
S&P83
EV/EBITDA?10.3CHEAP▾
Peers100
S&P80
EV/Sales?3.33FAIR▾
Peers100
S&P56
Returns & Efficiency
ROE?75.7%STRONG▾
Peers50
S&P95
ROA?61.8%STRONG▾
Peers50
S&P97
Cash Flow & Enterprise
FCF?$79.4M
Enterprise Value?$922.7M
Fundamentals ratios updated end of day